2020
Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature
Muiruri C, Longenecker CT, Meissner EG, Okeke NL, Pettit AC, Thomas K, Velazquez E, Bloomfield GS. Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. Progress In Cardiovascular Diseases 2020, 63: 142-148. PMID: 32057785, PMCID: PMC7237291, DOI: 10.1016/j.pcad.2020.02.006.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCardiovascular DiseasesComorbidityHealth Status DisparitiesHealthcare DisparitiesHIV InfectionsHIV Long-Term SurvivorsHumansPreventive Health ServicesPrognosisProtective FactorsRace FactorsRisk AssessmentRisk FactorsSocial Determinants of HealthSocial MarginalizationSocioeconomic FactorsViral LoadVulnerable PopulationsConceptsHuman immunodeficiency virusCardiovascular diseaseComorbid human immunodeficiency virusNarrative reviewSocial determinantsRacial disparitiesCommon social determinantsEthnic disparities persistEthnic groupsCVD morbidityImmunodeficiency virusClinical practiceTranslation of researchClinical researchDisparities persistDiseaseHealthDisparitiesGroupMorbidityReviewPersonsPrevention
2019
Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus
Alenezi F, Bloomfield GS, Okeke NL, Velagapudi P, Abudaqa L, Ijioma N, Dunning A, Alajmi H, Clement ME, Shah SH, Naggie S, Velazquez EJ. Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. The American Journal Of Cardiology 2019, 124: 966-971. PMID: 31371060, PMCID: PMC6887515, DOI: 10.1016/j.amjcard.2019.06.013.Peer-Reviewed Original ResearchConceptsLV ejection fractionHIV-1 RNA viral loadNormal LV ejection fractionRNA viral loadHuman immunodeficiency virusViral loadImmunodeficiency virusImmune statusGlobal longitudinal strain analysisNadir CD4 cell countPreclinical left ventricular dysfunctionDuke University Medical CenterCD4 cell countPlasma HIV RNALeft ventricular dysfunctionGlobal longitudinal strainCells/Longitudinal strain analysisUniversity Medical CenterCD4 cell count dataAbnormal GLSNadir CD4CD4 countHIV RNAVentricular dysfunctionEffects of a Cookstove Intervention on Cardiac Structure, Cardiac Function, and Blood Pressure in Western Kenya
Bloomfield GS, Kirwa K, Agarwal A, Eliot MN, Alenezi F, Carter EJ, Foster MC, Kimaiyo S, Lumsden R, Menya D, Mitter SS, Velazquez EJ, Vedanthan R, Wellenius GA. Effects of a Cookstove Intervention on Cardiac Structure, Cardiac Function, and Blood Pressure in Western Kenya. Journal Of The American Society Of Echocardiography 2019, 32: 427-430. PMID: 30665729, DOI: 10.1016/j.echo.2018.11.013.Peer-Reviewed Original Research
2017
Approaches to Sustainable Capacity Building for Cardiovascular Disease Care in Kenya
Barasa FA, Vedanthan R, Pastakia SD, Crowe SJ, Aruasa W, Sugut WK, White R, Ogola ES, Bloomfield GS, Velazquez EJ. Approaches to Sustainable Capacity Building for Cardiovascular Disease Care in Kenya. Cardiology Clinics 2017, 35: 145-152. PMID: 27886785, DOI: 10.1016/j.ccl.2016.08.014.Peer-Reviewed Original ResearchConceptsCardiovascular disease careHealth care infrastructureDiseases of povertyMiddle-income countriesDisease careCardiovascular diseaseNoncommunicable diseasesTherapeutic strategiesDiagnostic capacityHigh-quality medicationsCare infrastructureEpidemic levelsHealth careDiseasePhysical injuryCareTraffic accidents
2016
Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link?
Peña M, Dunning A, Schulte PJ, Durheim MT, Kussin P, Checkley W, Velazquez EJ. Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link? Respiratory Medicine 2016, 121: 4-12. PMID: 27888991, DOI: 10.1016/j.rmed.2016.10.009.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionAdverse cardiovascular eventsPulmonary functionCause mortalityCardiovascular eventsCardiac hospitalizationCardiac functionDecreased LVEFNormal left ventricular ejection fractionSingle tertiary care medical centerTertiary care medical centerCox proportional hazards modelLeft heart remodelingRight heart dysfunctionAdverse cardiovascular outcomesRight ventricular functionTertiary care centerVentricular ejection fractionVentricular internal dimensionLeft heart structuresLeft heart sizeProportional hazards modelMultivariable linear regressionDecreased FVCCardiovascular outcomesCoronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal Of Medicine 2016, 374: 1511-1520. PMID: 27040723, PMCID: PMC4938005, DOI: 10.1056/nejmoa1602001.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupArtery diseaseIschemic cardiomyopathySevere left ventricular systolic dysfunctionGuideline-directed medical therapyLeft ventricular systolic dysfunctionMajor secondary outcomesCoronary artery bypassPrimary outcome eventVentricular systolic dysfunctionArtery bypass surgeryCohort of patientsRate of deathSystolic dysfunctionBypass surgeryMedian durationSecondary outcomesSurvival benefitEjection fractionHeart failurePrimary outcome
2015
Current and emerging modalities for detection of cardiotoxicity in cardio-oncology
Khouri MG, Klein MR, Velazquez EJ, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. Future Cardiology 2015, 11: 471-484. PMID: 26235924, PMCID: PMC5558528, DOI: 10.2217/fca.15.16.Peer-Reviewed Original ResearchMeSH KeywordsCardiac Imaging TechniquesCardiotoxicityCardiovascular DiseasesDiagnostic Techniques, CardiovascularHumansNeoplasmsConceptsEarly detectionLife-saving cancer therapyCurative-intent therapyCancer-specific mortalityCancer-specific survivalCardiovascular risk factorsDetection of cardiotoxicityFunctional capacity testingNovel adjuvant therapyDegree of cardiotoxicityAdjuvant therapyCardiovascular morbidityCardiovascular mortalityCardiovascular dysfunctionCardiovascular injuryBlood biomarkersRisk factorsEarly preventionCancer treatmentCardiotoxicityTherapyMortalityCancer therapyDiagnostic toolInjuryImplementation of Management Strategies for Diabetes and Hypertension From Local to Global Health in Cardiovascular Diseases
Bloomfield GS, Wang TY, Boulware LE, Califf RM, Hernandez AF, Velazquez EJ, Peterson ED, Li JS. Implementation of Management Strategies for Diabetes and Hypertension From Local to Global Health in Cardiovascular Diseases. Global Heart 2015, 10: 31-38. PMID: 25754564, PMCID: PMC4754665, DOI: 10.1016/j.gheart.2014.12.010.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseNetwork-based careFuture cardiovascular diseasePopulation risk stratificationUniversity Health CentreSuccessful treatment interventionsChronic conditionsHealth centersTreatment interventionsHypertensionDiabetesImproved healthGlobal healthMajor causal factorDiseaseHealthManagement strategiesCausal factorsPrevalenceCare
2014
HIV and Noncommunicable Cardiovascular and Pulmonary Diseases in Low- and Middle-Income Countries in the ART Era
Bloomfield GS, Khazanie P, Morris A, Rabadán-Diehl C, Benjamin LA, Murdoch D, Radcliff VS, Velazquez EJ, Hicks C. HIV and Noncommunicable Cardiovascular and Pulmonary Diseases in Low- and Middle-Income Countries in the ART Era. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: s40-s53. PMID: 25117960, PMCID: PMC4133739, DOI: 10.1097/qai.0000000000000257.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCardiovascular DiseasesDeveloping CountriesHIV InfectionsHumansLung DiseasesResearchRisk FactorsConceptsHIV-positive patientsAntiretroviral therapyHIV infectionMiddle-income countriesPulmonary diseaseCoronary artery disease/myocardial infarctionLong-term HIV infectionEffective antiretroviral therapyHIV-seropositive patientsLong-term morbidityPulmonary arterial hypertensionObstructive lung diseaseHIV-positive personsLong-term outcomesChronic noncommunicable diseasesEffective prevention strategiesPotential adverse effectsPulmonary complicationsArterial hypertensionHeart failureLung diseasePulmonary conditionsMyocardial infarctionEarly recognitionART eraClinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease
Holmqvist F, Thomas KL, Broderick S, Ersbøll M, Singh D, Chiswell K, Shaw LK, Hegland DD, Velazquez EJ, Daubert JP. Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease. EP Europace 2014, 17: 978-985. PMID: 25164430, DOI: 10.1093/europace/euu211.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseHeart diseaseDuke University Medical CenterMajor cardiovascular outcomesMajor cardiovascular eventsNative coronary arteriesUniversity Medical CenterPR interval durationCV eventsCardiovascular eventsCardiovascular outcomesCause mortalityCoronary angiographyDuke DatabankClinical outcomesAtrial fibrillationPoor outcomeCoronary arterySignificant stenosisSinus rhythmCardiovascular diseaseMedical CenterHigh riskPatientsRelevant covariates
2013
Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. The American Journal Of Medicine 2013, 126: 501-508. PMID: 23541376, DOI: 10.1016/j.amjmed.2013.01.007.Peer-Reviewed Original ResearchConceptsSystolic blood pressureHigh-risk hypertensive patientsPrimary end pointBlood pressure levelsSystolic bloodBlood pressureCardiovascular deathCardiovascular eventsCardiovascular outcomesCoronary eventsEnd pointHypertensive patientsMyocardial infarctionSystolic blood pressure levelsAvoiding Cardiovascular EventsSystolic Hypertension (ACCOMPLISH) trialTotal myocardial infarctionBlood pressure groupMajor cardiovascular eventsMean patient ageNonfatal myocardial infarctionCardiovascular event ratesRenal end pointsLower blood pressureTreatment of hypertension
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney International 2011, 81: 568-576. PMID: 22189843, DOI: 10.1038/ki.2011.417.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBiomarkersBlack or African AmericanBlood PressureCalcium Channel BlockersCardiovascular DiseasesChi-Square DistributionCreatinineDiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionIncidenceKaplan-Meier EstimateKidneyKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesUp-RegulationConceptsHigh cardiovascular riskNon-black patientsSerum creatinineCardiovascular riskEnd-stage renal diseaseBlood pressure goalsHypertensive black patientsAcute hemodynamic effectsEffective antihypertensive treatmentKidney disease progressionGlomerular filtration rateDouble-blinded mannerEvent-driven trialDisease end pointsACCOMPLISH trialAntihypertensive treatmentRenal outcomesEGFR lossHemodynamic effectsRenal diseaseBlack patientsBlack ethnicityFiltration rateDisease progressionPatientsResponses of mental stress–induced myocardial ischemia to escitalopram treatment: Background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial
Jiang W, Velazquez EJ, Samad Z, Kuchibhatla M, Martsberger C, Rogers J, Williams R, Kuhn C, Ortel TL, Becker RC, Pristera N, Krishnan R, O'Connor CM. Responses of mental stress–induced myocardial ischemia to escitalopram treatment: Background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. American Heart Journal 2011, 163: 20-26. PMID: 22172432, PMCID: PMC3254211, DOI: 10.1016/j.ahj.2011.09.018.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaCoronary heart diseaseStable coronary heart diseaseStress-induced myocardial ischemiaMyocardial ischemiaMental Stress–Induced Myocardial IschemiaSelective serotonin reuptake inhibitor (SSRI) treatmentStress testingSerotonin reuptake inhibitor treatmentEjection fraction reductionReuptake inhibitor treatmentMental stress testingPsychometric questionnairesEffects of SSRIsIschemic ST changesInduced Myocardial IschemiaAbnormal wall motionAdult patientsEscitalopram treatmentSSRI treatmentPoor outcomeTreatment trialsPlatelet activityHeart diseaseRisk factorsHypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya
Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, Kimaiyo S. Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya. PLOS ONE 2011, 6: e22288. PMID: 21779407, PMCID: PMC3136516, DOI: 10.1371/journal.pone.0022288.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCardiovascular DiseasesFemaleHIV SeropositivityHumansHypertensionKenyaMaleMiddle AgedObesityRisk FactorsYoung AdultConceptsPrevalence of hypertensionOverweight/obesityLarge HIV treatment programCardiovascular risk factorsHIV treatment programsLogistic regression analysisRisk factorsSystolic/diastolic blood pressureAssociated cardiovascular risk factorsTreatment programMultiple logistic regression analysisHIV-seropositive individualsHIV-seropositive patientsDiastolic blood pressureOverweight/obesePrevalence of HIVPercent of menAge categoriesOrdinal logistic regression analysisRegression analysisHigher age categoriesElectronic medical recordsWestern KenyaCD4 countSeropositive patientsChronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: An academic model for countering the epidemic
Bloomfield GS, Kimaiyo S, Carter EJ, Binanay C, Corey GR, Einterz RM, Tierney WM, Velazquez EJ. Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: An academic model for countering the epidemic. American Heart Journal 2011, 161: 842-847. PMID: 21570512, PMCID: PMC3093664, DOI: 10.1016/j.ahj.2010.12.020.Peer-Reviewed Original ResearchMeSH KeywordsAfrica South of the SaharaCardiovascular DiseasesChronic DiseaseEpidemicsHumansLung DiseasesRisk FactorsConceptsPulmonary diseaseChronic diseasesNoncommunicable diseasesChronic noncommunicable diseasesMaternal diseaseWorldwide epidemicPulmonary medicinePatient careWorldwide deathsClinical researchDiseaseCardiovascular medicineMajor causeUnprecedented burdenInternational academic partnershipsCareSaharan AfricaWestern KenyaEpidemicBurdenAcademic partnershipsTraining curriculumResearch training curriculumMedicineMyocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1617-1625. PMID: 21463153, PMCID: PMC3290901, DOI: 10.1056/nejmoa1100358.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesCombined Modality TherapyCoronary Artery BypassCoronary Artery DiseaseEchocardiography, StressFemaleFollow-Up StudiesHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaMyocardiumProportional Hazards ModelsStatistics, NonparametricTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsCoronary artery diseaseVentricular dysfunctionMedical therapyMyocardial viabilityArtery diseaseViable myocardiumSurvival benefitBaseline variablesIschemic left ventricular dysfunctionDifferential survival benefitSubstudy of patientsCoronary artery bypassLeft ventricular dysfunctionDobutamine echocardiographyUnderwent assessmentPatientsCABGDysfunctionTreatment assignmentTherapyMyocardiumDiseaseGreater likelihoodMortalityTrialsCoronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1607-1616. PMID: 21463150, PMCID: PMC3415273, DOI: 10.1056/nejmoa1100356.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupRate of deathArtery diseasePrimary outcomeMajor secondary outcomesCoronary artery bypassPrimary end pointArtery bypass surgeryLeft ventricular dysfunctionTreatment of patientsVentricular dysfunctionBypass surgerySecondary outcomesEjection fractionHeart failureCABGPatientsTherapyEnd pointHospitalizationDeath
2010
Evidence for the efficacy of ARBs across the cardiovascular continuum
Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP. Evidence for the efficacy of ARBs across the cardiovascular continuum. Current Medical Research And Opinion 2010, 26: 1203-1218. PMID: 20302552, DOI: 10.1185/03007991003712159.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsCardiovascular DiseasesHumansRisk FactorsConceptsAngiotensin II receptor blockersPatient populationARB classCV continuumPre-specified risk factorsMajor CV outcomesII receptor blockersPrimary prevention studiesCardiovascular disease riskAdditional patient populationsDifferent patient populationsNumerous patient populationsMajor literature databasesCardiovascular continuumCV eventsCV morbidityCV outcomesReceptor blockersSecondary preventionACE inhibitorsAntihypertensive agentsOngoing trialsPrevention StudyRisk factorsDisease riskRenal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity